Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Diagnostics Celebrates Success at MEDICA 2012

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
Attendance statistics highlight interest in new point-of-care tools.

EKF Diagnostics’ success at MEDICA 2012 has been highlighted by a list of impressive statistics. The worldwide manufacturer of point-of-care (POC) diagnostic tools attracted numerous visitors to find out more about the 10 key products displayed on its 100m2 stand.  Generating the greatest interest was the European launch of two new POC products: the Quo-Lab glycated haemoglobin (HbA1c) analyser for the affordable management of diabetes; and the STAT-SiteTM M ßHB strip-based analyser, for highly accurate near patient testing of ketosis.

Over 200 product demos and 66 customer meetings were given to delegates to demonstrate the qualities of EKF Diagnostics’ newest POC solutions. The semi-automated, CE marked Quo-Lab analyser monitors HbA1c, which is increasingly used in the detection and management of diabetes, and provides a highly accurate, affordable and easy-to-use technology for GP surgeries, diabetes clinics and laboratories. The STAT-SiteTM M ßHB has been developed for the measurement of ß-Hydroxybutyrate (ßHB), the main ketone produced during ketosis, and provides a quantitative and accurate assessment of patients displaying symptoms of ketosis. This makes ketosis testing easier and more affordable in POC settings.

Nine free mini-seminars, attended by 121 delegates, outlined the benefits of using Quo-Lab and STAT SiteTM M ßHB, alongside the Lactate Scout+ for lactate measurement in obstetrics, and the Hemo-Control Manager for haemoglobin analysis and data management. A range of clinical chemistry reagents were also presented by EKF product specialists, including the ß-Hydroxybutyrate (ßHB) LiquiColor® Reagent System developed by EKF subsidiary, Stanbio Laboratory, which is relied on by 13 of the USA’s top 25 diabetes and endocrinology hospitals for its rapid and reliable results.

According to Julian Baines, Group CEO, “The launch of our two new POC products for diabetes and ketosis testing at Medica this year was a tremendous success, which was reflected in the interest shown by the large number of attendees visiting our stand. We were delighted with the response to our seminar series. The seminars provided a great way to update customers Quo-Lab and STAT-Site M BHB and also brush up their knowledge on established EKF products.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
Combined with the recent acquisition of Seperation Technology the purchases strengthen EKF’s product and services offering.
Tuesday, April 22, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!